TrialCancer communications (London, England)2021

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.

Zhi Peng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.